Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. Nall says the company has also managed to win a US patent for its liquid biopsy cancer testing technology.
Full interview: Biocept 'one of the first' liquid biopsy providers to detect cancer biomarkers in fluid around brain
Quick facts: Biocept Inc
Price: 4.47 USD
Market Cap: $59.87 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE